# Nuclide record psa-kinetics (term). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/terms/psa-kinetics/>
  a schema:DefinedTerm ;
  nuclide:kind "term" ;
  schema:identifier "psa-kinetics" ;
  schema:name "PSA kinetics: PSA doubling time and PSA density"@en ;
  schema:alternateName "PSA doubling time"@en, "PSADT"@en, "PSA velocity"@en, "PSA density"@en, "PSAD"@en, "PSA kinetics"@en, "PSA rise"@en, "rising PSA"@en, "biochemical recurrence PSA threshold"@en, "PSA nadir"@en, "PSA response"@en, "PSA50"@en, "PSA90"@en, "PSA progression"@en ;
  schema:description "How fast PSA is rising matters more than its level: a doubling time under ten months after surgery or radiotherapy, or under nine months in castration-resistant disease, marks the men whose cancer is moving quickly and who benefit from earlier hormone therapy or a PSMA scan, while PSA density (PSA divided by prostate volume) helps decide who needs a biopsy at all."@en ;
  schema:url <https://nuclide.cc/terms/psa-kinetics/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  nuclide:related <https://nuclide.cc/technologies/psma-pet/>, <https://nuclide.cc/drugs/enzalutamide/> ;
  nuclide:indications <https://nuclide.cc/indications/prostate-bcr/>, <https://nuclide.cc/indications/prostate-nmcrpc/>, <https://nuclide.cc/indications/prostate-mcrpc/> .